Effectiveness of the air-filled technique to reduce the dead space in syringes and needles during ChAdox1-n CoV vaccine administration

Abstract

In the current study, we calculated the vaccine volume and amount of dead space in a syringe and needle during ChAdox1-n CoV vaccine administration using the air-filled technique, to reduce dead space in syringe and needle that administer up to 12 doses per vial. The hypothetical situation uses a vial with a similar size as the ChAdox1-n CoV vial. We used distilled water (6.5 ml), to fill the same volume as five vials of ChAdox1-n CoV. When 0.48 ml of distilled water is drawn according to the number on the side of the barrel, an additional 0.10 ml of air can be used in the dead space of the distilled water in the syringe and needle for 60 doses, which can be divided into an average of 0.5 ml dose. ChAdox1-n CoV was administered using a 1-mL syringe and 25G needle to administer ChAdox1-n CoV vaccine into 12 doses using this air-filled technique. The volume of the recipient vaccine will be increase by 20% and save the budget of a low dead space syringe (LDS).

• Download figure
• Open in new tab

Competing Interest Statement

All the authors declare that they have no competing interests.

Clinical Trial

NCT04961385

Funding Statement

This work was supported by a grant from Navamindradhiraj University

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The experiment was performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. This study was approved by the Vajira Institutional Review Board, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University. The vaccine used was authorized by the Thai FDA and the Department of Medical Science (DMS).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes